Medicine
Strensiq 40 mg/1 mL injection
Strensiq 40 mg/1 mL injection is a prescription medicine containing Asfotase alfa for subcutaneous use, marketed by Alexion Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
STRENSIQ vials must be stored in the original carton until the time of use…
Key facts
- Active ingredient (INN)
- Asfotase alfa
- Brand
- Strensiq
- Strength
- 40 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 12 vials of 1 mL
- Marketing authorisation holder
- Alexion Pharmaceuticals
- Manufacturer
- Alexion Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- STRENSIQ vials must be stored in the original carton until the time of use under refrigerated conditions at 2°C to 8°C (36°F to 46°F) and protected from light. Once removed from refrigeration, STRENSIQ should be administered within 3 hours. DO NOT FREEZE OR SHAKE.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A16AB13 Asfotase alfa
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 October 2015
- Identifiers
- RxCUI 1720263, 1720268, 1720271 +5DailyMed set ID 3387574f-5eaa-4501-a71d-4cbfbd563031NDC 25682-016Application BLA125513
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 12 vial in 1 carton / 1 mL in 1 vial | 25682-016-12 | Alexion Pharmaceuticals | 23 October 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Asfotase alfa
Clinical summary
Asfotase alfa is a tissue-nonspecific alkaline phosphatase indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). It is available as injection for subcutaneous use. MedsAcross supplies Asfotase alfa for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Asfotase alfaFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- STRENSIQ prescribing information (Alexion Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Strensiq: European public assessment report (EPAR) · European Medicines Agency
Need Strensiq 40 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.